AR057423A1 - 2,4-diamino-pirimidinas como inhibidores de aurora, preparacion farmaceutica y uso del compuesto para preparar un medicamento - Google Patents
2,4-diamino-pirimidinas como inhibidores de aurora, preparacion farmaceutica y uso del compuesto para preparar un medicamentoInfo
- Publication number
- AR057423A1 AR057423A1 ARP060102827A ARP060102827A AR057423A1 AR 057423 A1 AR057423 A1 AR 057423A1 AR P060102827 A ARP060102827 A AR P060102827A AR P060102827 A ARP060102827 A AR P060102827A AR 057423 A1 AR057423 A1 AR 057423A1
- Authority
- AR
- Argentina
- Prior art keywords
- membered
- nrcrc
- group
- nrfrf
- radical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de la formula general (1), estos compuestos son adecuados para el tratamiento de enfermedades que se caracterizan por una proliferacion excesiva o anomala de células, así como a su uso para la produccion de un medicamento con las propiedades mencionadas precedentemente. Reivindicacion 1: Compuestos de la formula general (1), R1 es un radical, sustituido por R5 y eventualmente por uno o varios R4, seleccionados del grupo consistente en cicloalquilo C3-10 y heterocicloalquilo de 3-8-miembros; R2 es un radical, eventualmente sustituido por uno o varios R4, seleccionado del grupo consistente en alquilo C1-6, cicloalquilo C3-10, heterocicloalquilo de 3-8-miembros, arilo C6-15 y heteroarilo de 5-12- miembros; R3 es un radical seleccionado del grupo consistente en hidrogeno, halogeno, -CN, -NO2, alquilo C1-4, haloalquilo C1-4, cicloalquilo C3-10, cicloalquilalquilo C4-16 y arilalquilo C7-16; R4 es un radical seleccionado del grupo consistente en Ra, Rb y Ra sustituido por uno o varios Rc y/o Rb, iguales o distintos R5 es un radical adecuado seleccionado del grupo consistente en -C(O)Rc, -C(O)NRcRc, -S(O)2Rc, -N(Rf)S(O)2Rc, -N(Rf)C(O)Rc, -N(Rf)C(O)ORc, y N(Rf)C(O)NRcRc; cada Ra está seleccionado independientemente de los demás, del grupo consistente en alquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroalquilo de 2-6-miembros, heterocicloalquilo de 3-8-miembros, heterocicloalquilalquilo de 4-14-miembros, heteroarilo de 5-12-miembros y heteroarilalquilo de 6-18-miembros; cada Rb es un radical adecuado y en cada caso está consistente en =O, -ORc, haloalquiloxi C1-3, -OCF3, =S, -SRc, =NRc, =NORc, -NRcRc, halogeno, -CF3, -CN, -NC, -OCN, -SCN, -NO2, -S(O)Rc, -S(O)2Rc, -S(O)2ORc, -S(O)NRcRc, -S(O)2NRcRc, -OS(O)Rc, -OS(O)2Rc, -OS(O)2ORc, -OS(O)2NRcRc, -C(O)Rc, -C(O)ORc, -C(O)NRcRc, -CN(Rf)NRcRc, -CN(OH)Rc, -CN(OH)NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)NRcRc, -OCN(Rf)NRcRc, -N(Rf)C(O)Rc, -N(Rf)C(S)Rc, -N(Rf)S(O)2Rc, -N(Rf)C(O)ORc, -N(Rf)C(O)NRcRc, -[N(Rf)C(O)]2Rc, -N[C(O)]2Rc, -N[C(O)]2ORc, -[N(Rf)C(O)]2ORc y -N(Rf)CN(Rf)NRcRc; cada Rc es, independientemente de los demás, hidrogeno o un radical eventualmente sustituido por uno o varios Rd y/o Re iguales o distintos, seleccionado del grupo consistente en alquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-11, arilo C6-10, arilalquilo C7-16, heteroalquilo de 2-6 miembros, heterocicloalquilo de 3-8 miembros, heterocicloalquilalquilo 4-14 miembros, heteroarilo de 5-12 miembros y heteroarilalquilo de 6-18 miembros, cada Rd es, independientemente de los demás, hidrogeno o un grupo radical eventualmente sustituido por uno o varios Re y/o Rf iguales o distintos, seleccionado del grupos consistente en alquilo C1-6, cicloalquilo C3-8, cicloalquilalquilo C4-11, arilo C6-10, arilalquilo C7-16, heteroalquilo de 2-6-miembros, heterocicloalquilo de 3-8 miembros, heterocicloalquilalquilo 4-14 miembros, heteroarilo de 5-12 miembros y heteroarilalquilo de 6-18 miembros; cada Re es un radical adecuado y está está seleccionado, independientemente de los demás, del grupo consistente en =O, -ORf, haloaliloxi C1-3, -OCF3, =S, -SRf, =NRf, =NORf, -NRfRf, halogeno, -CF3, -CN, -NC, -OCN, -SCN, -NO2, -S(O)Rf, -S(O)2Rf, -S(O)2ORf, -S(O)NRfRf, -S(O)2NRfRf, -OS(O)Rf, -OS(O)2Rf, -OS(O)2ORf, -OS(O)2NRfRf, -C(O)Rf, -C(O)ORf, -C(O)NRfRf, -CN(Rg)NRfRf, -CN(OH)Rf, - C(NOH)NRfRf, -OC(O)Rf, -OC(O)ORf, -OC(O)NRfRf, -OCN(Rg)NRfRf, -N(Rg)C(O)Rf, -N(Rg)C(S)Rf, -N(Rg)S(O)2Rf, -N(Rd)C(O)ORf, -N(Rg)C(O)NRfRf, y -N(Rg)CN(Rf)NRfRf; cada Rf es, independientemente de los demás, hidrogeno o un radical eventualmente sustituido por uno o varios Rg, iguales o distintos, seleccionado del grupo consistente en alquilo C1-6, cicloalquilo C3-8, cicloalquilalquilo C4-11, arilo C6-10, arilalquilo C7-16, heteroalquilo de 2-6 miembros, heterocicloalquilo de 3-8 miembros, heterocicloalquilalquilo 4-14 miembros, heteroarilo de 5-12 miembros y heteroarilalquilo de 6-18 miembros; cada Rg es, independientemente de los demás, hidrogeno, alquilo C1-6, cicloalquilo C3-8, cicloalquilalquilo C4-11, arilo C6-10, arilalquilo C7- 16, heteroalquilo de 2-6 miembros, heterocicloalquilo de 4-14 miembros, heterocicloalquilo de 5-12 miembros, y heteroarilalquilo de 6-18 miembros; eventualmente en forma de sus tautomeros, sus racematos, sus enantiomeros, sus diastereomeros y sus mezclas, así como eventualmente sus sales de adicion de ácido farmacologicamente inocuas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05106007 | 2005-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057423A1 true AR057423A1 (es) | 2007-12-05 |
Family
ID=35431858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102827A AR057423A1 (es) | 2005-07-01 | 2006-06-30 | 2,4-diamino-pirimidinas como inhibidores de aurora, preparacion farmaceutica y uso del compuesto para preparar un medicamento |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20070032514A1 (es) |
| EP (1) | EP1902037B1 (es) |
| JP (1) | JP5179357B2 (es) |
| KR (1) | KR20080031362A (es) |
| CN (1) | CN101213179A (es) |
| AR (1) | AR057423A1 (es) |
| AT (1) | ATE441639T1 (es) |
| AU (1) | AU2006264958B2 (es) |
| BR (1) | BRPI0613096A2 (es) |
| CA (1) | CA2613664A1 (es) |
| CY (1) | CY1109644T1 (es) |
| DE (1) | DE502006004750D1 (es) |
| DK (1) | DK1902037T3 (es) |
| EA (1) | EA016358B1 (es) |
| EC (1) | ECSP078060A (es) |
| ES (1) | ES2330045T3 (es) |
| IL (1) | IL188452A (es) |
| MX (1) | MX2007015992A (es) |
| MY (1) | MY142496A (es) |
| NO (1) | NO20076059L (es) |
| NZ (1) | NZ565475A (es) |
| PE (1) | PE20070121A1 (es) |
| PL (1) | PL1902037T3 (es) |
| PT (1) | PT1902037E (es) |
| SI (1) | SI1902037T1 (es) |
| TW (1) | TWI369351B (es) |
| UA (1) | UA92355C2 (es) |
| UY (1) | UY29636A1 (es) |
| WO (1) | WO2007003596A1 (es) |
| ZA (1) | ZA200709763B (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1763514A2 (en) * | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| GB2420559B (en) * | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| PE20080068A1 (es) * | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
| MX2009004426A (es) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
| CA2673184A1 (en) * | 2006-12-22 | 2008-07-03 | Boehringer Ingelheim International Gmbh | New compounds |
| WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| WO2010022125A1 (en) * | 2008-08-20 | 2010-02-25 | Schering Corporation | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| AU2009282574B2 (en) | 2008-08-20 | 2014-08-21 | Merck Sharp & Dohme Corp. | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| AR072937A1 (es) * | 2008-08-20 | 2010-09-29 | Schering Corp | Derivados de piridina y pirimidina sustituida y su uso en el tratamiento de infecciones virales |
| US8470834B2 (en) | 2008-08-20 | 2013-06-25 | Merck Sharp & Dohme Corp. | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
| US8815872B2 (en) * | 2008-09-08 | 2014-08-26 | Merck Patent Gmbh | Macrocyclics pyrimidines as aurora kinase inhibitors |
| AR074210A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| TW201024281A (en) * | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| US20110071158A1 (en) | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| US8410126B2 (en) * | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| EP2440548A1 (en) | 2009-06-10 | 2012-04-18 | Abbott Laboratories | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
| JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| US8729265B2 (en) | 2009-08-14 | 2014-05-20 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US8466155B2 (en) | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| US20120107304A1 (en) * | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| MX2012014158A (es) | 2010-06-04 | 2013-02-07 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2). |
| PT3124483T (pt) | 2010-11-10 | 2019-10-02 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2 |
| AU2012221927B2 (en) * | 2011-02-25 | 2016-04-28 | Yuhan Corporation | Diaminopyrimidine derivatives and processes for the preparation thereof |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| US10202356B2 (en) | 2013-03-14 | 2019-02-12 | Tolero Pharmaceuticals, Inc. | JAK2 and ALK2 inhibitors and methods for their use |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| MX2016007898A (es) | 2013-12-20 | 2016-10-07 | Signal Pharm Llc | Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos. |
| GB2538476B (en) | 2014-05-08 | 2019-03-20 | Tosoh F Tech Inc | 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same |
| US10710983B2 (en) | 2016-06-27 | 2020-07-14 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and method for making and using the compounds |
| JP2021524835A (ja) * | 2018-04-05 | 2021-09-16 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | Ａｘｌキナーゼ阻害剤およびその使用 |
| JP2021530554A (ja) | 2018-07-26 | 2021-11-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 異常なａｃｖｒ１発現を伴う疾患を処置するための方法およびそこで使用するためのａｃｖｒ１阻害剤 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MEP13408A (en) * | 2001-05-29 | 2010-06-10 | Bayer Schering Pharma Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| WO2003002666A1 (fr) * | 2001-06-27 | 2003-01-09 | Polyplastics Co., Ltd. | Composition de resine ignifuge |
| UY27487A1 (es) * | 2001-10-17 | 2003-05-30 | Boehringer Ingelheim Pharma | Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación |
| RS51752B (sr) * | 2002-07-29 | 2011-12-31 | Rigel Pharmaceuticals | Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1694652A1 (en) * | 2003-12-19 | 2006-08-30 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| CN1976905A (zh) * | 2004-03-30 | 2007-06-06 | 大正制药株式会社 | 嘧啶衍生物以及与其应用有关的治疗方法 |
| BRPI0511138A (pt) * | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento de desenvolvimento celular anormal |
| EP1763514A2 (en) * | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| GB2420559B (en) * | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| CA2590250A1 (en) * | 2004-12-14 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrimidine inhibitors of erk protein kinase and uses therof |
| AU2006327871A1 (en) * | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
-
2006
- 2006-06-27 US US11/475,468 patent/US20070032514A1/en not_active Abandoned
- 2006-06-28 MY MYPI20063091A patent/MY142496A/en unknown
- 2006-06-28 PE PE2006000752A patent/PE20070121A1/es not_active Application Discontinuation
- 2006-06-29 UY UY29636A patent/UY29636A1/es not_active Application Discontinuation
- 2006-06-30 DK DK06763989T patent/DK1902037T3/da active
- 2006-06-30 UA UAA200800924A patent/UA92355C2/ru unknown
- 2006-06-30 CA CA002613664A patent/CA2613664A1/en not_active Abandoned
- 2006-06-30 EA EA200800172A patent/EA016358B1/ru not_active IP Right Cessation
- 2006-06-30 AU AU2006264958A patent/AU2006264958B2/en not_active Ceased
- 2006-06-30 MX MX2007015992A patent/MX2007015992A/es active IP Right Grant
- 2006-06-30 BR BRPI0613096-8A patent/BRPI0613096A2/pt not_active IP Right Cessation
- 2006-06-30 AR ARP060102827A patent/AR057423A1/es unknown
- 2006-06-30 SI SI200630479T patent/SI1902037T1/sl unknown
- 2006-06-30 TW TW095123919A patent/TWI369351B/zh not_active IP Right Cessation
- 2006-06-30 AT AT06763989T patent/ATE441639T1/de active
- 2006-06-30 DE DE502006004750T patent/DE502006004750D1/de active Active
- 2006-06-30 WO PCT/EP2006/063736 patent/WO2007003596A1/de not_active Ceased
- 2006-06-30 NZ NZ565475A patent/NZ565475A/en not_active IP Right Cessation
- 2006-06-30 ES ES06763989T patent/ES2330045T3/es active Active
- 2006-06-30 JP JP2008518857A patent/JP5179357B2/ja not_active Expired - Fee Related
- 2006-06-30 EP EP06763989A patent/EP1902037B1/de not_active Not-in-force
- 2006-06-30 CN CNA2006800240865A patent/CN101213179A/zh active Pending
- 2006-06-30 PL PL06763989T patent/PL1902037T3/pl unknown
- 2006-06-30 KR KR1020087002717A patent/KR20080031362A/ko not_active Ceased
- 2006-06-30 PT PT06763989T patent/PT1902037E/pt unknown
-
2007
- 2007-11-13 ZA ZA200709763A patent/ZA200709763B/xx unknown
- 2007-11-26 NO NO20076059A patent/NO20076059L/no not_active Application Discontinuation
- 2007-12-27 IL IL188452A patent/IL188452A/en not_active IP Right Cessation
- 2007-12-27 EC EC2007008060A patent/ECSP078060A/es unknown
-
2009
- 2009-11-25 CY CY20091101222T patent/CY1109644T1/el unknown
-
2011
- 2011-06-14 US US13/159,787 patent/US20110251174A1/en not_active Abandoned
-
2013
- 2013-03-26 US US13/850,711 patent/US20130281429A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057423A1 (es) | 2,4-diamino-pirimidinas como inhibidores de aurora, preparacion farmaceutica y uso del compuesto para preparar un medicamento | |
| AR076620A1 (es) | 2,4 DIAMINOPIRIMIDINAS, COMPOSICIONES FARMACEUTICAS, PROCESOS DE PREPARACIoN Y SU USO COMO MEDICAMENTO. | |
| AR078513A1 (es) | Pirimidinas y composiciones farmaceuticas que las comprenden | |
| AR074209A1 (es) | Derivados de pirimidina utiles para el tratamiento del cancer | |
| AR074210A1 (es) | Derivados de pirimidina como inhibidores de ptk2-quinasa | |
| AR051743A1 (es) | Tiazolil - dihidro- indazoles | |
| AR060890A1 (es) | Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos | |
| CO2019000932A2 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR082699A1 (es) | Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto | |
| MX2017009244A (es) | Compuestos de pirazina novedosos para el tratamiento de enfermedades infecciosas. | |
| AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
| UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
| JO3447B1 (ar) | 2-(مورفولين-4-يل)-7،1-نفثيريدينات | |
| AR071673A1 (es) | Procedimiento para la preparacion de compuestos pirazolicos sustituidos en posiciones 1,3,4 | |
| MX379474B (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales | |
| AR072538A1 (es) | Derivados de indolinonas, composiciones farmacéuticas y usos | |
| UY36170A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| AR074358A1 (es) | Derivados de pirazina como inhibidores de la fosfodiesterasa 10 | |
| CY1116439T1 (el) | Τριαζολοπυριδινες | |
| AR083358A1 (es) | Compuestos de furo[3,2-d]pirimidina | |
| UY33483A (es) | Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento. | |
| PE20142376A1 (es) | Fluormetil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR072845A1 (es) | 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas. | |
| MX2020010949A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |